Warts is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Warts have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Warts compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Warts overview
Warts, caused by the human papillomavirus (HPV), are common skin growths that can appear on various parts of the body. While generally harmless, warts can be unsightly and occasionally painful, particularly when located on weight-bearing areas like the feet. HPV spreads through direct skin contact or contaminated surfaces, making prevention challenging. Although many warts resolve on their own over time, treatment options such as over-the-counter remedies, cryotherapy, or laser therapy may be sought for faster removal. Proper hygiene and avoiding direct contact with warts can help prevent their spread. While typically benign, persistent or bothersome warts may warrant medical attention for evaluation and treatment.
For a complete picture of PTSR and LoA scores for drugs in Warts, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
